Meta-analysis shows anti-VEGF agents comparable in efficacy

Article

All anti-vascular endothelial growth factor (VEGF) agents improve visual acuity compared with laser photocoagulation, but there is insufficient evidence to distinguish the performance of any single anti-VEGF agent over another, according to results from a recently-conducted meta-analysis from researchers at the Institute for Clinical and Economic Review. The safety of bevacizumab also remains uncertain.

All anti-vascular endothelial growth factor (VEGF) agents improve visual acuity compared with laser photocoagulation, but there is insufficient evidence to distinguish the performance of any single anti-VEGF agent over another, according to results from a recently-conducted meta-analysis from researchers at the Institute for Clinical and Economic Review. The safety of bevacizumab also remains uncertain.

These researchers included reports of treatment of diabetic macular oedema with aflibercept, bevacizumab, pegaptanib or ranibizumab published between January 2000 and June 30, 2012, with comparisons to laser photocoagulation, sham injections, or other controls. Fifteen randomized controlled trials and eight observational studies were included. No direct comparative studies could be found. Efficacy measures were based on best-corrected visual acuity (BCVA) in terms of letters gained. Direct meta-analyses were conducted on BCVA for each anti-VEGF agent, and indirect comparisons were also done for each anti-VEGF pairing.

All agents improved visual acuity compared with control, with a range of improvement of 4 to 9 letters, and outcomes were consistent across multiple time points. There were no statistically significant or consistent differences between any agents in regards to changes in BCVA or the percentage of patients who gained more than 10 letters. No differences in adverse events, including ocular events, myocardial infarction, stroke, other cardiovascular events, or death were seen in comparisons of aflibercept, pegaptanib and ranibizumab; data of adverse events with bevacizumab were under reported.

To view an abstract of this study, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.